AbbVie (ABBV) shares have witnessed various movements with a decline of 1.73%, losses of 0.29% in two instances, and even a plummet concurrent with the market rise. However, the company's stock also rose by 16% YTD, accentuating its appeal among dividend aristocratic stocks boasting over 3% yield. Despite curtailing its Q1 and 2025 EPS forecast due to increased costs from IPR&D and milestones expenses, AbbVie persisted. It showcased oncology innovations as the share price dipped by 6%. The profit forecast for 2025 was again revised due to acquisition costs.Efforts toward growth remained steady, including the acquisition of Nimble Therapeutics for bolstering its immunology pipeline. Collaboration agreements with Gubra and Neomorph to focus on obesity treatment and molecular glue degraders for oncology and immunology set optimistic growth paths. Its Q4 earnings are slated for a decline. Institutional ownership increased by 73% as the stock continued to impress.Nevertheless, the company's long-term outlook remains sturdy despite trimming full-year guidance. Balance sheet health and a raised dividend indicated solid financial performance. The firm also ventured into the ulcerative colitis treatment space in Canada expanding SKYRIZI's availability.
Abbvie ABBV News Analytics from Mon, 28 Oct 2024 07:00:00 GMT to Fri, 04 Apr 2025 00:32:42 GMT -
Rating 1
- Innovation 4
- Information 7
- Rumor -4
